Lindsay Rosenwald
Chief Executive Officer at FORTRESS BIOTECH, INC.
Net worth: 6 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Weiss | M | 58 |
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then.
Helocyte, Inc.
 Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY.
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY.
Cellvation, Inc.
| 19 years |
| Neil Herskowitz | M | 67 | 10 years | |
| Xiao Qin Lu | M | 49 | 12 years | |
| James Oliviero | M | 48 | 21 years | |
| David Jin | M | 34 | - | |
| Frank Taffy | M | - |
Helocyte, Inc.
Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY.
Cellvation, Inc.
| 9 years |
| William Gray | M | 36 | 8 years | |
| Jaclyn Jaffe | F | - | - | |
| Jay Kranzler | M | 66 |
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | 7 years |
| Manuel Litchman | M | 70 | 7 years | |
| Claude Maraoui | M | 57 | 10 years | |
| Adam Chill | M | 56 | 10 years | |
| J. Lobell | M | 61 |
Paramount BioCapital, Inc.
 Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 19 years |
| Alexandra MacLean | M | 57 | 3 years | |
| Lung S. Yam | M | - |
Cyprium Therapeutics, Inc.
Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | 7 years |
| Michael S. Spector | M | - |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | - |
| George Avgerinos | M | 71 | 11 years | |
| Malcolm Hoenlein | M | 80 | 10 years | |
| Brian Achenbach | M | 59 | 7 years | |
| Justin Smith | M | 49 | 3 years | |
| Ernest Galvan | M | 62 | - | |
| Ramsey Alloush | M | 39 | - | |
| Samuel Berry | M | - | 8 years | |
| Joseph Benesch | M | 57 | 3 years | |
| Greg Furrow | M | - | 5 years | |
| Kevin Lorenz | M | 59 | 5 years | |
| James Murphy | M | 67 | - | |
| Barry Salzman | M | 62 | 8 years | |
| Michael Zelefsky | M | 63 | 7 years | |
| Faith Charles | F | 62 | 2 years | |
| Curtis Oltmans | M | 60 | 3 years | |
| Jimmie Harvey | M | 72 | 16 years | |
| Christian Béchon | M | 63 | 6 years | |
| Dov Klein | M | 72 | 9 years | |
| Miranda Toledano | F | 47 | 3 years | |
| Jessica Yeaman | F | - | 6 years | |
| Nicole McCloskey | F | - | - | |
| Robert Sexton | M | - | 2 years | |
| Rick Bodmer | M | - | 2 years | |
| Daniel DiPietro | M | - |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 19 years |
| Srinivas Sidgiddi | M | - | 3 years | |
| Scott Reines | M | 77 | 8 years | |
| Robert Nevin | M | 56 | - | |
| Bruce Dezube | M | - | 3 years | |
| Jaclyn Jaffe | F | - | - | |
| Suzanne Lentzsch | M | - |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | - |
| Rodney H. Falk | M | - |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | - |
| Susan Sobolov | M | - |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | 7 years |
| Andrew Zwible | M | - | 4 years | |
| Michael Ryan | M | - | 6 years | |
| Lynn E. Bayless | F | - | 4 years | |
| Debra Manning | F | - | 5 years | |
| Paul Brooke | M | 77 |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | 6 years |
| Eric Rowinsky | M | 67 | 14 years | |
| Peter Carney | M | 38 | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jose M. Aldeanueva | M | 55 | - | |
| Robyn Hunter | F | 62 | 11 years | |
| Jeff Paley | M | 55 | 4 years | |
| Alan Auerbach | M | 54 |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 6 years |
| Glenn L. Cooper | M | 71 | 4 years | |
| David J. Horin | M | 56 | 2 years | |
| Bobby Sandage | M | 70 | 2 years | |
| Harlan Weisman | M | 71 | 1 years | |
| Joseph Vazzano | M | 40 | 5 years | |
| Noah Beerman | M | 62 | 2 years | |
| Raymond Tesi | M | 68 | 3 years | |
| Jack Kaye | M | 80 | 10 years | |
| Gary Gemignani | M | 58 | 1 years | |
| Scott Boilen | M | 57 | 8 years | |
| Barry Rodgers | M | 84 | - | |
| Jeffrey J. Gutovich | M | 67 | - | |
| Sadik Kassim | M | - | 2 years | |
| Knut Niss | M | - | - | |
| Elizabeth Ingram | F | 59 | 3 years | |
| Evan Renov | M | - |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 5 years |
| Thomas G. Moore | M | 72 | 1 years | |
| Jaideep Gogtay | M | 58 | 3 years | |
| Nishant Saxena | M | 48 | - | |
| David Barrett | M | 48 | - | |
| Charles R. Eyler | M | 76 |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 5 years |
| Stephen B. Pudles | M | 63 | - | |
| David Tanen | M | 52 |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States.
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 8 years |
| Ronald Bentsur | M | 58 | 6 years | |
| Dale Ritter | M | 73 | 2 years | |
| Arthur Asher Kornbluth | M | 64 | 2 years | |
| Stephen Rocamboli | M | 52 |
Paramount BioCapital, Inc.
Paramount BioCapital, Inc. Investment ManagersFinance Paramount BioCapital, Inc. is an alternative investment manager. The private company is based in New York, NY and has subsidiaries in the United States. | 8 years |
| Arie Belldegrun | M | 74 |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 6 years |
| Matthew Wein, | - | - | - | |
| Michael Rogers | M | 64 | 2 years | |
| Morris Laster | M | 60 | 5 years | |
| Akhtar Samad | M | 64 | 4 years | |
| Ronald Renaud | M | 55 | 1 years | |
| BILL Kessler | M | 57 | 2 years | |
| Peter J. Cochrane | M | - |
Temple University School of Medicine
| 3 years |
| Russell Ellison | M | 76 |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 3 years |
| Kenneth Hoberman | M | 59 | 8 years | |
| Sean Power | M | 42 | 5 years | |
| Eric Rose | M | 73 | - | |
| Arturo Molina | M | 65 |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lindsay Rosenwald
- Personal Network
